Optimal patient selection for stereotactic body radiotherapy - Authors' reply

Lancet Oncol. 2019 Dec;20(12):e662. doi: 10.1016/S1470-2045(19)30747-8.

Authors

Douglas H Brand¹, Alison C Tree¹, Emma Hall², Nicholas van As³; PACE Trial Investigators

Affiliations

¹ Department of Uro-oncology, The Royal Marsden Hospital, London, SW3 6JJ, UK; The Institute of Cancer Research, London, UK.
² The Institute of Cancer Research, London, UK.
³ Department of Uro-oncology, The Royal Marsden Hospital, London, SW3 6JJ, UK; The Institute of Cancer Research, London, UK. Electronic address: nicholas.vanas@rmh.nhs.uk.

PMID: 31797788
DOI: 10.1016/S1470-2045(19)30747-8

No abstract available

Publication types

Letter
Comment

MeSH terms

Dose Fractionation, Radiation
Humans
Male
Patient Selection
Prostatic Neoplasms*
Radiosurgery*
Radiotherapy, Intensity-Modulated*